Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Burns-Pipeline Review, H2 2016

Burns-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Burns-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Burns-Pipeline Review, H2 2016', provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burns

The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burns therapeutics and enlists all their major and minor projects

The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burns

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burns

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Burns Overview 10

Therapeutics Development 11

Pipeline Products for Burns-Overview 11

Pipeline Products for Burns-Comparative Analysis 12

Burns-Therapeutics under Development by Companies 13

Burns-Therapeutics under Investigation by Universities/Institutes 15

Burns-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Burns-Products under Development by Companies 20

Burns-Products under Investigation by Universities/Institutes 22

Burns-Companies Involved in Therapeutics Development 23

Adocia 23

AlgiPharma AS 24

Amarantus Bioscience Holdings, Inc. 25

American Gene Technologies International Inc. 26

Biogenomics Limited 27

CytoTools AG 28

Destiny Pharma Limited 29

Lakewood-Amedex Inc 30

Madam Therapeutics B.V. 31

MediWound Ltd. 32

Mitochon Pharmaceuticals, Inc. 33

Phosphagenics Limited 34

Se-cure Pharmaceuticals Ltd. 35

Sinclair Pharma Plc 36

Stratatech Corporation 37

Tissue Therapies Limited 38

USV Pvt Ltd 39

Burns-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Combination Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

(cerium nitrate hexahydrate + silver sulfadiazine)-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

A-3APO-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

AG-110-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

albumin (recombinant)-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ALLO-ASC-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Biochaperone PDGF-BB-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

bromelains-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Cell Therapy for Dermatology and Immunology-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

epidermal growth factor biosimilar-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Gene Therapy for Burns-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

IMSP-001-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

lidocaine hydrochloride-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Monoclonal Antibody Conjugate to Target TNF-alpha for Burns, Inflammation and Wounds-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

MP-101-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Neu-2000-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Nu-2-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Oligomer G for Wounds And Burns-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

P-12-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

P-148-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

PEP-04-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

SC-106-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

silver sulfadiazine-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecules for Burn-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

sodium hypochlorite-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

VF-002-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

XF-70-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Burns-Dormant Projects 85

Burns-Discontinued Products 88

Burns-Product Development Milestones 89

Featured News & Press Releases 89

Jun 07, 2016: MediWound's NexoBrid Receives Reimbursement in Italy 89

May 19, 2016: MediWound's NexoBrid Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting 89

May 02, 2016: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting 90

Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized 92

Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS) 92

Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters 93

Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania 94

Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid 95

Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to USD 112 Million for Development and Procurement of NexoBrid for the U.S. 95

Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress 96

Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress 98

Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting 102

Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting 102

Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns 103

Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine 104

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Figures

Number of Products under Development for Burns, H2 2016 11

Number of Products under Development for Burns-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 40

Number of Products by Top 10 Targets, H2 2016 42

Number of Products by Stage and Top 10 Targets, H2 2016 42

Number of Products by Top 10 Mechanism of Actions, H2 2016 44

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 44

Number of Products by Routes of Administration, H2 2016 46

Number of Products by Stage and Routes of Administration, H2 2016 46

Number of Products by Top 10 Molecule Types, H2 2016 48

Number of Products by Stage and Top 10 Molecule Types, H2 2016 48

List of Tables

Number of Products under Development for Burns, H2 2016 11

Number of Products under Development for Burns-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Comparative Analysis by Unknown Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Burns-Pipeline by Adocia, H2 2016 23

Burns-Pipeline by AlgiPharma AS, H2 2016 24

Burns-Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 25

Burns-Pipeline by American Gene Technologies International Inc., H2 2016 26

Burns-Pipeline by Biogenomics Limited, H2 2016 27

Burns-Pipeline by CytoTools AG, H2 2016 28

Burns-Pipeline by Destiny Pharma Limited, H2 2016 29

Burns-Pipeline by Lakewood-Amedex Inc, H2 2016 30

Burns-Pipeline by Madam Therapeutics B.V., H2 2016 31

Burns-Pipeline by MediWound Ltd., H2 2016 32

Burns-Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016 33

Burns-Pipeline by Phosphagenics Limited, H2 2016 34

Burns-Pipeline by Se-cure Pharmaceuticals Ltd., H2 2016 35

Burns-Pipeline by Sinclair Pharma Plc, H2 2016 36

Burns-Pipeline by Stratatech Corporation, H2 2016 37

Burns-Pipeline by Tissue Therapies Limited, H2 2016 38

Burns-Pipeline by USV Pvt Ltd, H2 2016 39

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 45

Number of Products by Stage and Route of Administration, H2 2016 47

Number of Products by Stage and Molecule Type, H2 2016 49

Burns-Dormant Projects, H2 2016 85

Burns-Dormant Projects (Contd..1), H2 2016 86

Burns-Dormant Projects (Contd..2), H2 2016 87

Burns-Discontinued Products, H2 2016 88

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adocia

AlgiPharma AS

Amarantus Bioscience Holdings, Inc.

American Gene Technologies International Inc.

Biogenomics Limited

CytoTools AG

Destiny Pharma Limited

Lakewood-Amedex Inc

Madam Therapeutics B.V.

MediWound Ltd.

Mitochon Pharmaceuticals, Inc.

Phosphagenics Limited

Se-cure Pharmaceuticals Ltd.

Sinclair Pharma Plc

Stratatech Corporation

Tissue Therapies Limited

USV Pvt Ltd

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com